Stati Uniti - Ingliż - NLM (National Library of Medicine)

tya pharmaceuticals - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see .) precautions: drug interactions nifedipine must not be used in cases of cardiogenic shock. nifedipine extended-release tablets are contraindicated in patients with a known hypersensitivity to any component of the tablet.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

a-s medication solutions - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions, drug interactions .)  nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

bryant ranch prepack - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 60 mg - nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. - (classical effort-associated angina) (classical effort-associated angina

Stati Uniti - Ingliż - NLM (National Library of Medicine)

bryant ranch prepack - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 20 mg - nifedipine capsules, usp are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. nifedipine capsules, usp are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers an

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 60 mg - tablet, modified release - excipient ingredients: iron oxide red; titanium dioxide; hypromellose; magnesium stearate; povidone; purified talc; macrogol 4000; carbomer 934p; lactose monohydrate; colloidal anhydrous silica; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 30 mg - tablet, modified release - excipient ingredients: carbomer 934p; titanium dioxide; povidone; purified talc; iron oxide red; macrogol 4000; hypromellose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

greenstone llc - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine capsule is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine capsules may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. nifedipine capsule is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or

Stati Uniti - Ingliż - NLM (National Library of Medicine)

a-s medication solutions - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine extended-release tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine extended-release tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. nifedipine extended-release tablet is indicated for the management of chronic st

Stati Uniti - Ingliż - NLM (National Library of Medicine)

lupin pharmaceuticals inc - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - i. vasospastic angina nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. ii. chronic stable angina (classical effort-associated angina) nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain

Stati Uniti - Ingliż - NLM (National Library of Medicine)

american health packaging - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - i. vasospastic angina nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. ii. chronic stable angina (classical effort-associated angina) nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients wh